相似文献
1
Vaccination plus previous infection: protection during the omicron wave in Brazil.
Lancet Infect Dis. 2022 Jul;22(7):945-946. doi: 10.1016/S1473-3099(22)00288-2. Epub 2022 May 16.
2
Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2-11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study.
Lancet Reg Health Am. 2024 Apr 23;34:100750. doi: 10.1016/j.lana.2024.100750. eCollection 2024 Jun.
3
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
Lancet Infect Dis. 2023 Apr;23(4):435-444. doi: 10.1016/S1473-3099(22)00729-0. Epub 2022 Nov 24.
4
Indirect effectiveness of COVID-19 vaccines in the pre-omicron and omicron periods: A nation-wide test-negative case-control study in Brazil.
Int J Infect Dis. 2024 Nov;148:107241. doi: 10.1016/j.ijid.2024.107241. Epub 2024 Sep 18.
5
Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.
PLoS Med. 2023 Jan 11;20(1):e1004156. doi: 10.1371/journal.pmed.1004156. eCollection 2023 Jan.
6
Protection against Omicron from Vaccination and Previous Infection in a Prison System.
N Engl J Med. 2022 Nov 10;387(19):1770-1782. doi: 10.1056/NEJMoa2207082. Epub 2022 Oct 26.
7
Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Lancet Infect Dis. 2023 Jul;23(7):799-805. doi: 10.1016/S1473-3099(23)00060-9. Epub 2023 Mar 13.
8
Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections.
Nat Commun. 2022 Aug 12;13(1):4738. doi: 10.1038/s41467-022-31838-8.
9
Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study.
Clin Infect Dis. 2023 Feb 8;76(3):e142-e147. doi: 10.1093/cid/ciac604.
10
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil.
Nat Commun. 2022 Jul 18;13(1):4154. doi: 10.1038/s41467-022-31839-7.
引用本文的文献
1
Effectiveness of a single COVID-19 mRNA vaccine dose in individuals with prior SARS-CoV-2 infection: a systematic review.
Commun Med (Lond). 2025 May 3;5(1):151. doi: 10.1038/s43856-025-00882-y.
2
Characteristics and risk factors associated with COVID-19 reinfection in Hong Kong: a retrospective cohort study.
Epidemiol Infect. 2025 Feb 7;153:e30. doi: 10.1017/S0950268825000172.
3
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2425147. doi: 10.1080/21645515.2024.2425147. Epub 2024 Dec 12.
4
Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.
Front Public Health. 2024 Aug 26;12:1457266. doi: 10.3389/fpubh.2024.1457266. eCollection 2024.
5
COVID-19 Vaccine Uptake and Effectiveness by Time since Vaccination in the Western Cape Province, South Africa: An Observational Cohort Study during 2020-2022.
Vaccines (Basel). 2024 Jun 5;12(6):628. doi: 10.3390/vaccines12060628.
6
Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination.
Vaccines (Basel). 2024 May 22;12(6):564. doi: 10.3390/vaccines12060564.
7
Protection of prior SARS-CoV-2 infection, COVID-19 boosters, and hybrid immunity against Omicron severe illness: A population-based cohort study of five million residents in Canada.
PLoS One. 2024 Feb 23;19(2):e0299304. doi: 10.1371/journal.pone.0299304. eCollection 2024.
8
Counterfactual analysis of the 2023 Omicron XBB wave in China.
Infect Dis Model. 2024 Jan 8;9(1):195-203. doi: 10.1016/j.idm.2023.12.006. eCollection 2024 Mar.
9
Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination.
Vaccines (Basel). 2023 Dec 28;12(1):36. doi: 10.3390/vaccines12010036.
10
Impact of Vaccination and Nonpharmaceutical Interventions With Possible COVID-19 Viral Evolutions Using an Agent-Based Simulation.
AJPM Focus. 2023 Oct 10;3(1):100155. doi: 10.1016/j.focus.2023.100155. eCollection 2024 Feb.
本文引用的文献
1
Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study.
Nat Commun. 2022 Sep 30;13(1):5736. doi: 10.1038/s41467-022-33378-7.
2
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
Lancet Infect Dis. 2022 Jun;22(6):791-801. doi: 10.1016/S1473-3099(22)00140-2. Epub 2022 Apr 1.
3
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
Zotero 插件